Risvodetinib, an investigational c-Abl inhibitor, met its primary safety and tolerability end points and showed promising signals of functional and pathologic improvement in a 12-week, phase 2 study of patients with early and untreated Parkinson…
Risvodetinib Demonstrates Potential Functional Benefit in Early Parkinson Disease | NeurologyLive
